This plot shows the median serum estrogen (E2) concentration (in pg/mL) versus total Weekly Estrogen patch dose (mg/wk) from five different references ranging from 2000 to 2019.
The data set from Smith et. al (2019) is for castrate-resistant prostate cancer men (CRPC), who are not taking ADT.
Overall, the serum E2 concentration increases as the number of E2 patches used per week (Total weekly E2 dose) increases. For reference, the E2 range for a healthy, pre-menopausal woman is [200-400] pg/mL.
There is no evidence of a rollover or saturation in the serum E2 as the applied E2 patch dose increases. In fact, the dataset from Smith et. al (2019) is best fit by a rising quadratic curve (red dashed line), instead of a straight (linear) line.
Differences between the linear fit (green dashed line) and the quadratic fit (red dashed line) may be due to men belonging to different PCa groups (i.e., castrate-sensitive or castrate-resistant).
These curves can be used to titrate the serum E2 concentration to a desired target by adjusting the number of patches used per week. When using a common 100 microgram/24 Hr estrogen patch, then 10 patches per week provides a weekly absorbed dose of 1.0 mg E2 per week.
Written by
janebob99
To view profiles and participate in discussions please or .
Richard Wassersug, a co-author of the definitive book about ADT management, has been using TDE for over twenty years. You can find him on the HU forums. He uses TDE gel daily and avoids the swapping of patches. Using the gel, I'm told by those who use it, requires one to experiment with the amount to use daily by monitoring one's E, T and PSA with blood tests until the correct amount of gel is obtained.
Prof. Wassersug is a fantastic resource and a friend. I phone and FaceTime with him on a regular basis. He's probably the leading expert in North America on transdermal estrogen.
I agree that the gel may be more difficult to titrate than patches. In principle, equivalent doses should give equivalent responses, all other things being equal.
I'm not using TDE get yet, but as they say, it is probably on my horizon. I am not using any HT at this point in my PCa care, but my PSA is inching upward following a RARP in '19 and then SAT in '22 and BCR when it reached 2,1. My PSA is at .73 now.
I have osteoporosis and have been urged to use the SOC bone mineral density (BMD) drugs. I'm resisting those SOC drugs (Prolia & Zometa) because of their SEs and considering the use of TDE at a level that might reduce my testosterone level slightly from its present 350-400 level, but offer BMD help without the SEs of the alternative SOC BMD meds.
I'm reading the supporting med journal articles about TDE and BMD health.
so, Lupron showed a slight decrease in BMD, and patch a slightly higher increase in BMD...correct? More important IMO would be what are the differences between the 2 when a man already has low BMD ? If a man is "normal " BMD, probably not a big risk of approaching osteoporosis.....it is the osteopenic men who have the big worry I think.
Actually, a +6% change in BMD on estrogen is a big change, not a slight increase.
Other spots on the body, Hip, femur, forearm, etc. were also measured in the PATCH study (see attached Figures). For these other locations, Lupron produced a negative 5-6% drop in BMD, versus a +1% change for estrogen. Those are big changes in BMD.
Older, non-cancerous, men often have osteopenia and osteoporosis because their T and E have naturally declined significantly. This leads to increased risks of fracture.
I had osteoporosis decades ago, before I was later diagnosed with hypogonadism due to a pituitary microadenoma. Now that my T and E are normalized, I have normal BMD.
All men doing Lupron ADT should have a yearly DEXA scan, or every 6-months.
Estrogen "add-back" can help prevent osteopenia and osteoporosis (it's dose dependent).
Is one of those addback?? That is, normal Lupron dose plus estrogen supplement? Hmmm, I thought loss of BMD was permanent, more or less, so this is encouraging. I'd be happy just to not worsen BMD while doing RT + ADT? Wonder f anyway in hell a Kaiser Doc would agree to something different. All I can do is bring some ammunition to meeting in 2 weeks.....truly appreciate the best you have found ! I haven't looked..PATCH trial is so close to endpoint.....any preliminary results published??? I was one of the 1st...maybe the 1st, at our regional Kaiser to undergo MRI fusion biopsy....took an appeal!!! Would be great to be first to try some form of ADT that would pose less risk in so many areas!!!! I've been dreading it.....even delaying treatment for my 4+5 !!!!! I don't know how perfectly well men, except the PCa diagnosis, are able to quickly rush into treatment that can ultimately be almost as damaging to QOL IMMEDIATELY as the PCa is eventually?
I started at PSA 8 5 years ago, went from 8 two years ago to 12 a month ago....urologist was not panicked, but I was slightly!! PSMA PETS aren't perfect, but mine still negative??? With 4+5 , horse might already be out of barn, and the RT of little value....bring on the ADT of some form...sigh. Meanwhile , we try to live normally!!!
I believe that figure from Ockrim is for high-dose estrogen patch therapy, taken from the PATCH trial. I don't have data handy for low-dose add back estrogen. It may be in of my 20+ papers on estrogen, though.
Ruth Langley told me recently that the phase-III PATCH trial results will be published this Fall. Stay tuned !
My email address is janebob99@lobo.net. If you send me an email, I will send you my complete library of estrogen papers.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Best ways for dealing with ADT side effects?
Transdermal estrogen/estradiol as monotherapy for Prostate Cancer
Optimal SBRT dose
